Purpose: The aim of the study was to investigate the plasma homocysteine levels in patients with retinal vein occlusion (RVO) in order to reveal whether hyperhomocysteinemia was a risk factor for RVO. Methods: Thirty-three consecutive patients diagnosed to have RVO of any type and 25 age- and sex-matched controls without RVO were included in this prospective case-control study. Data regarding age, sex, history of hypertension, diabetes mellitus, other vascular events, glaucoma, medications and smoking habits were obtained from all subjects. Several laboratory tests relating to vascular disease including cholesterol, triglyceride and hematocrit were checked. The plasma total homocysteine (tHcy) level was measured by high-performance liquid chromatography (normal range: 5–15 µmol/l). Plasma folate, vitamin B12 and creatinine levels were also studied since these vitamins and impairment of renal function might affect plasma tHcy values. Results: Patients with RVO had a significantly higher tHcy level (median: 11.7 µmol/l, range: 7.2–25 µmol/l) compared to controls (median: 10.3 µmol/l, range: 6.7–13.4 µmol/l; p = 0.005). Nine of 33 patients with RVO (27.3%) had an elevated plasma tHcy level, whereas none of the controls had an abnormal tHcy value (p = 0.004). Plasma folate, vitamin B12 and creatinine levels were comparable between the two groups (p > 0.05). Conclusions: The present study suggests an association between hyperhomocysteinemia and RVO. Further controlled studies with a large number of cases are needed to investigate the exact role of hyperhomocysteinemia in RVO.

Keywords:
Retinal vein occlusion, Homocysteine, Hyperhomocysteinemia
1.
Amato SS: Genetic and metabolic disorders; in Behrman RE, Kliegman R (eds): Nelson Essentials of Pediatrics. Philadelphia, Saunders, 1990, pp 139–140.
2.
Measurement and use of total plasma homocysteine. ASHG/ACMG Statement. Am J Genet 1998;63:1541–1543.
3.
McCully KS: Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111–128.
4.
Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM: Total plasma homocysteine and cardiovascular risk profile: The Hordaland Homocysteine Study. JAMA 1995;274:1526–1533.
5.
Boushey CJ, Baresford SAA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049–1057.
6.
Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997;277:1775–1781.
7.
Vine AK: Hyperhomocysteinemia: A risk factor for central retinal vein occlusion. Am J Ophthalmol 2000;129:640–644.
8.
Cahill M, Karabatzaki M, Meleady R, Refsum H, Ueland P, Shields D, Mooney D, Graham I: Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000;84:154–157.
9.
Brown BA, Marx JL, Ward TP, Hollifield RD, Dick JS, Brozetti JJ, Howard RS, Thach AB: Homocysteine: A risk factor for retinal venous occlusive disease. Ophthalmology 2002;109:287–290.
10.
Weger M, Stanger O, Deutschmann H, Temmel W, Renner W, Schmut O, Semmelrock J, Haas A: Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:286–290.
11.
Weger M, Stanger O, Deutschmann H, Temmel W, Renner W, Schmut O, Quehenberger F, Semmelrock J, Haas A: Hyperhomocyst(e)inemia, but not MTHFR C677T mutation, as a risk factor in branch retinal vein occlusion. Ophthalmology 2002;109:1105–1109.
12.
Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA, Al-Attas OS: Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol 2002;12:495–500.
13.
Larsson J, Hultberg B, Hillarp A: Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand 2000;78:340–343.
14.
Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, Hykin PG: Plasma homocysteine, MTHFR C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001;85:1313–1315.
15.
Hayreh SS, Zimmermann MB, Podhajsky P: Hematological abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:180–196.
16.
Champe PC, Harvey RA: Lippincott’s Illustrated Reviews: Biochemistry, ed 2. Philadelphia, Lippincott, 1994, pp 248–249.
17.
Selhub J, Jacques PF, Wilson PW, et al: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–2698.
18.
Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomized trials. Homocysteine Lowering Trialists’ Collaboration. BMJ 1998;316:894–898.
19.
Brattström L, Wilcken DEL, Öhrvik J, Brudin L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The results of a meta-analysis. Circulation 1998;98:2520–2526.
20.
Loewenstein A, Goldstein M, Winder A, et al: Retinal vein occlusion associated with MTHFR mutation. Ophthalmology 1999;106:1817–1820.
21.
Bellamy MF, McDowell IF, Ramsey MW, et al: Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998;98:1848–1852.
22.
Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–1050.
23.
Dudman NPB: An alternative view of homocysteine. Lancet 1999;354:2072–2074.
24.
Fermo I, Arcelloni C, De Vecchi E, et al: High-performance liquid chromatographic method with fluorescence detection for the determination of total homocysteine in plasma. J Chromatogr 1992;593:171–176.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.